EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-SMA-05(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Spinal Muscular Atrophy (SMA) is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Spinal Muscular Atrophy (SMA) is a progressive genetic neuromuscular disease caused by deficiency in the survival motor neuron (SMN) protein, leading to motor neuron loss.
Biological Rationale & Paracrine Action:
Administered as an adjunctive, exploratory protocol using umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to deliver neurotrophic support, modulate local spinal neuroinflammation, and support existing motor neuron viability.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with genetically confirmed SMA (Types 1, 2, 3, or 4) with documented SMN1 deletion/mutation.
Mandatory Pre-Procedure Diagnostics:
Mandatory Diagnostic Screening: Up-to-date baseline pulmonary function testing (FVC/SpO2), formal spine alignment imaging (scoliosis assessment), cardiac baseline, and current disease-modifying therapy status.
Strict Safety Exclusion Parameters:
Active acute respiratory infection/failure, tracheostomy dependency without stable mechanical ventilation, uncontrolled refractory seizures, or acute systemic infection.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Endurance & Fatigue: Reduced physical exhaustion during daily activities and therapy sessions.
- Motor Tone & Stability: Modest support for proximal limb strength, head control, and sitting balance.
- Bulbar Support: Incremental support for swallowing coordination and vocal projection.
- Notice: Outcomes vary significantly by SMA type, age, and baseline functional state.
Documented Procedural Risks & Limits:
- Transient post-puncture headache, localized site discomfort, mild nausea, or low-grade fever (resolving within 24–48 hours).
- Risks associated with pediatric sedation or lumbar puncture in the presence of spinal deformity or instrumentation.
- No Guaranteed Response: Cellular therapy cannot regenerate lost SMN genes or replace fully degenerated motor neuron pools.
Patient Experience: Stem Cell Therapy for Spinal Muscle Atrophy (SMA) | Patient from Sweden
Watch this clinical case study demonstrating observed motor milestone preservation, muscle endurance, and physical rehabilitation outcomes at Stem Cell Therapy Center India.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accreditation
Hospital-based clinical environment operating under Joint Commission International (JCI) and NABH accreditations.
Multidisciplinary Neuromuscular Board
Integrated evaluations by pediatric neurologists, spine surgeons, pulmonologists, and pediatric intensivists.
Ethical Standards
Regulated under an Institutional Ethics Committee registered with the Department of Health Research (DHR) / CDSCO.
Objective Triage
Patients are accepted only if clinical evaluation indicates potential adjunctive utility without compromising primary care.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Consultation
Remote telehealth call with treating neurologists to review expectations, genetics, and safety.
Visa & Travel Facilitation
Official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Manager
Dedicated liaison for English/multilingual translation, administrative coordination, and admission procedures.
Post-Discharge Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, coordinating reports directly with the patient’s home neuromuscular specialist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Barrier-Free Transfers
Private, wheelchair-accessible airport pick-up and hospital transfers.
Accessible Stays
Hospital suites equipped for assistive equipment (suction, cough-assist, BiPAP power backup) or vetted accessible serviced apartments near the facility.
Specialized Care Amenities
Custom nutritional planning (dysphagia-adapted or gastrostomy tube formulations), local SIM registration, and 24/7 nursing availability.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 5 to 7 days comprehensive in-hospital stay.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Spinal Muscular Atrophy (SMA)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Phase 1 Clinical Trial of Intrathecal Allogeneic Adipose-Derived Stem Cells in SMA Type 1
Mohseni, A., Hamidieh, A. A., et al. (2022). An open-label phase 1 clinical trial of the allogeneic side population adipose-derived mesenchymal stem cells in SMA type 1 patients. Neurological Sciences, 43(1), 399–408.
Pilot Study of Intrathecal Mesenchymal Stromal Cell Injections in SMA Type 1
Andolina, M., et al. (2012). Treatment of Spinal Muscular Atrophy with Intrathecal Mesenchymal Cells. International Journal of Stem Cells, 5(1), 73–75.
Observational Cohort on Allogeneic Stem Cell Interventions in Severe SMA
Villanova, M., & Bach, J. R. (2015). Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. American Journal of Physical Medicine & Rehabilitation, 94(5), 410–415.
Neural Stem Cell Grafting & Phenotypic Rescue in SMA Models
Corti, S., Nizzardo, M., Simone, C., et al. (2008). Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. Journal of Clinical Investigation, 118(10), 3316–3330.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research issued by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), as well as guidelines from the Central Drugs Standard Control Organisation (CDSCO), stem cell application for Spinal Muscular Atrophy is classified as investigational and experimental. It is not approved as a standard therapy or cure. Families are strictly advised never to discontinue or delay approved standard therapies (including SMN-enhancing medications and standard respiratory/orthopedic care) in favor of investigational stem cell protocols.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.